A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma

Summary

The study is aimed at evaluating efficacy and safety of oglemilast in the treatment of stable mild to moderate persistent asthma. The study involves two weeks of run in period. This is a placebo controlled study. One of the four treatment arms is placebo. The duration of treatment is 12 weeks.

Timeline

Start

2008-10

Primary completion

2009-12

Completion

2010-01

Drugs

Indications